|
|
|
|
|
BioSpace
Clinical Catch-Up: February 10-14
|
|
|
|
It was a very busy week for clinical trial news. Here’s a look.
Kodiak Sciences announced positive safety, efficacy and durability data from its ongoing Phase Ib trial of KSI-301 in wet age-related macular degeneration (AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO). KSI-301 is an intravitreal anti-VEGF antibody biopolymer conjugate. They describe the data as promising with 420 doses in 130 patients.
vTv Therapeutics announced positive data from Part 2 of the Phase II Simplici-T1 trial of TTP399 in type 1 diabetes.
Read more
|
|
|
|
|
|
|
|
|
The Guardian
Pete Buttigieg 'won't take lectures' from Rush Limbaugh or any Trump supporter
|
|
|
|
Pete Buttigieg is “not going to be lectured on family values from the likes of Rush Limbaugh or anybody who supports Donald J Trump as the moral as well as political leader of the United States”, the Democratic presidential contender said on Sunday.
Limbaugh, a conservative talk radio host controversially honoured by Trump, caused controversy this week when he questioned whether Americans were ready to vote for a gay candidate for president.
Speaking on Fox News Sunday, Buttigieg added: “America has moved on and we should have politics of belonging that welcomes everybody.
Read more
|
|
|
|
|
|
|
|
|
Dove Press
Aptamers as Versatile Ligands for Biomedical and Pharmaceutical Applic | IJN
|
|
|
|
Aptamers are short RNA or single-stranded DNA comprise 20–80 nucleotides (Figure 1) that can fold into unique three-dimensional conformations to specifically bind to targets. Aptamers are intentionally designed oligonucleotide sequences that differ from naturally occurring ligands.1 They can specifically recognize and interact with diverse targets such as receptors, antigens, and biomarkers via van der Waals forces, hydrogen bonding, electrostatic interactions, stacking of flat moieties, and shape complementarity.2 Upon binding to targets, aptamers induce a series of biochemical effects, such as antagonism, agonism, suppression, and destruction.3,4 Aptamers can be synthesized through a systematic evolution of ligands by exponential enrichme...
Read more
|
|
|
|
|
|
|
|
|
Dove Press
lncRNA CCAT2 Enhanced Resistance of Glioma Cells Against Chemodrugs by
|
|
|
|
Glioma, stemming from gliocytes in the central nervous system, was responsible for more than a half of brain-related tumors,1 and it was usually categorized into astrocytoma, oligodendroglioma, vasculoma and mixed glioma as per its pathological traits.2 Annually, 22,070 people were newly diagnosed as cerebral tumor in the United States,3 and the death toll triggered by brain tumor reached up to 3.13/100,000 per year.4 Confronted with the frustrating prevalence and morbidity, surgery was preferred as the principal treatment for glioma, and adjuvant therapies included chemotherapy, radiotherapy and comprehensive chemoradiotherapy.5,6 Nevertheless, it was tough to completely eliminate tumor tissues that have metastasized elsewhere, and chemoto...
Read more
|
|
|
|
|
|
|
|
|
Springer
microRNAs Orchestrate Pathophysiology of Breast Cancer Brain Metastasis: Advances in Therapy
|
|
|
|
Abstract
Brain metastasis (BM) predominantly occurs in triple-negative (TN) and epidermal growth factor 2 (HER2)-positive breast cancer (BC) patients, and currently, there is an unmet need for the treatment of these patients. BM is a complex process that is regulated by the formation of a metastatic niche. A better understanding of the brain metastatic processes and the crosstalk between cancer cells and brain microenvironment is essential for designing a novel therapeutic approach. In this context, the aberrant expression of miRNA has been shown to be associated with BM.
Read more
|
|
|
|
|
|
|
|
|
European Society for Medical Oncology
ELCC 2017 | European Lung Cancer Conference
|
|
|
|
The 7h edition of the European Lung Cancer Conference (ELCC), took place 5-8 May 2017, in Geneva, Switzerland.
The European Lung Cancer Conference is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance science, disseminate education and improve the practice of lung cancer specialists worldwide.
Main themes:
New IASLC Staging
ESMO recommendations for thoracic malignancies
Immunotherapy: first-line treatment, biomarkers and combination approaches
SCLC and mesothelioma
Management and diagnosis of persistence in molecularly defined NSCLC
Management of brain metastases
News and updates from ELCC 2017 can be found on Twitter by ...
Read more
|
|
|
|
|
|
|
|
|
Yahoo Finance
PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer
|
|
|
|
MADRID and DUBLIN, Feb. 17, 2020 /PRNewswire/ -- PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announce that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the New Drug Application (NDA) seeking accelerated approval for lurbinectedin for the treatment of patients with Small Cell Lung Cancer (SCLC) who have progressed after prior platinum-containing therapy. The FDA has set a PDUFA target action date of August 16, 2020.
PharmaMar submitted the NDA to FDA in December 2019 based on data from the Phase II monotherapy basket trial, which included evaluation of lurbinectedin for the treatment of relapsed SCLC.
Read more
|
|
|
|
|
|
|
|
|
Yahoo Finance
Incyte Corporation (INCY) Company Profile & Facts - Yahoo Finance
|
|
|
|
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
Read more
|
|
|
|
|
|
|
|
|
Yahoo Finance
Angle PLC Announces Data demonstrates key advantages of Parsortix
|
|
|
|
Hamburg-Eppendorf developed validated standardised Parsortix protocols for use in future clinical trials
Parsortix harvested cells allow for "robust amplification of single cell DNA at excellent quality for subsequent molecular analysis"
GUILDFORD, ENGLAND / ACCESSWIRE / February 17, 2020 / ANGLE plc (AGL.L) (ANPCY), a world-leading liquid biopsy company, is pleased to announce that University Medical Centre Hamburg-Eppendorf has published results of work undertaken to assess the analytical and clinical performance of Parsortix in multiple metastatic cancer types with the main emphasis on metastatic breast cancer.
The work was completed as part of the pan-European CANCER-ID consortium funded by the European Innovative Medicine Initiative...
Read more
|
|
|
|
|
|
|
|
|
Yahoo Finance
The Week Ahead In Biotech: Agile, Baudax Bio, Merck and Esperion Await FDA Decisions
|
|
|
|
Biotech stocks were quiet in the week ending Feb. 14 amid some data readouts at a couple of conferences and earnings news flow from smid-cap companies.
The following are key biotech catalysts to look forward to for the unfolding week:
34th German Cancer Conference: Feb 19-22 in Berlin, Germany
International Association For The Study of Lung Cancer, or IASLC, 2020 Targeted Therapies of Lung Cancer Meeting: Feb. 19-22 in Santa Monica, California
Related Link: 13 Key NASH Drug Candidates To Watch For In A Potential -Billion Market
The FDA will rule on Agile Therapeutics Inc's (NASDAQ: AGR) hormonal contraceptive patch Twirla by the PDUFA action date of Sunday.
Read more
|
|
|
|
|
|
|
|
|
|
|
|
|
1. Oncology
CHU
solid immunotherapy is the use of the immune system to fight cancer. ERY974 is a bispecific antibody designed to elicit T cell activation and T cell-dependent cellular cytotoxicity by simultaneously binding to glypican-3, a protein expressed in certain cancers, and CD3 on the surface of T cells. A phase I clinical trial is evaluating ERY974 for the treatment of solid tumors.
Managed By:
3. Oncology
RG6026
relapsed or refractory non-Hodgkin's (anti-CD20 CD3 TCB) is a 2:1 format T cell-engaging bispecific antibody, designed to engage both CD20 on B cells and CD3 on T cells.
Read more
|
|
|
|
|
|
|
|
|
Twitter
OncLive.com NSCLC, lcsm: 16/02/2020 11:10:06
|
|
|
|
The findings add to the growing evidence of an “obesity paradox” in patients with cancer in which a high BMI is linked to an increased incidence of some malignancies but may offer protection from others #NSCLC #lcsm @cancerFCIC
Read more
|
|
|
|
|
|
|
|
|
Twitter
ASCO Publications JCOGO, lcsm: 16/02/2020 18:20:02
|
|
|
|
Unearthing EGFR Mutations and the Rewards of Persistence in Precision Oncology: Breaching the 10-Year Survival Barrier in Metastatic NSCLC With Active Disease https://t.co/vfzx8e6eyZ #JCOGO #lcsm
Read more
|
|
|
|
|
|
|
|
|
Twitter
Targeted Oncology lungcancer: 17/02/2020 05:00:06
|
|
|
|
Dr. Levy said research has come a long way in terms of the molecular driver identification in NSCLC. Initially, it started with testing for EGFR and ALK, but now there are a number of mutations that we can test for.
Read more
|
|
|
|
|
